Nutriband (NTRB) 10-Q 17 Sep 18 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jul. 31, 2018	Sep. 07, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Nutriband Inc.
Entity Central Index Key	1,676,047
Trading Symbol	NTRB
Amendment Flag	false
Current Fiscal Year End Date	--01-31
Document Type	10-Q
Document Period End Date	Jul. 31, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q2
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		21,824,100

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jul. 31, 2018	Jan. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 1,097,181
Inventories	54,606	4,133
Prepaid expenses	65,503	160,503
VAT receivable		263
Total Current Assets	1,217,290	164,899
PROPERTY and EQUIPMENT-net	3,816
OTHER ASSETS:
Deposit on acquisition	1,850,000
TOTAL ASSETS	3,071,106	164,899
CURRENT LIABILITIES:
Accounts payable and accrued expenses	73,120	12,341
Deferred revenue	49,000
Due to related parties		14,230
Notes payable	40,000	16,820
Total Current Liabilities	162,120	43,391
Commitments and Contingencies
STOCKHOLDERS' EQUITY:
Preferred stock, $.001 par value, 10,000,000 shares authorized, -0- outstanding
Common stock, $.001 par value, 100,000,000 shares authorized; 21,824,100 and 20,877,100 shares issued and outstanding at July 31, 2018 and January 31, 2018, respectively	21,824	20,877
Additional paid-in-capital	8,063,490	2,950,487
Accumulated other comprehensive loss	(48)	(446)
Accumulated deficit	(5,176,280)	(2,849,410)
Total Stockholders' Equity	2,908,986	121,508
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 3,071,106	$ 164,899

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jul. 31, 2018	Jan. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ .001	$ .001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ .001	$ .001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	21,824,100	20,877,100
Common stock, shares outstanding	21,824,100	20,877,100

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2018	Jul. 31, 2017	Jul. 31, 2018	Jul. 31, 2017
Income Statement [Abstract]
Revenue
Costs and expenses:
Cost of sales
Non-cash compensation	1,486,450		1,763,950
Selling, general and administrative expenses	392,322	92,962	562,920	128,579
Total Costs and Expenses	1,878,772	92,962	2,326,870	128,579
Loss from operations before Provision for income taxes	(1,878,772)	(92,962)	(2,326,870)	(128,579)
Provision for income taxes
Net loss	$ (1,878,772)	$ (92,962)	$ (2,326,870)	$ (128,579)
Net loss per common share-basic and diluted	$ (0.09)	$ 0	$ (0.11)	$ (0.01)
Weighted average common shares outstanding - basic and diluted	21,240,133	19,550,361	21,061,625	17,594,199
Other Comprehensive Income (Loss):
Net loss	$ (1,878,772)	$ (92,962)	$ (2,326,870)	$ (128,579)
Foreign currency translation adjustment	252	(1,471)	398	(1,567)
Total Comprehensive Loss	$ (1,878,520)	$ (94,433)	$ (2,326,472)	$ (130,146)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jul. 31, 2018	Jul. 31, 2017
Cash flows from operating activities:
Net loss	$ (2,326,870)	$ (128,579)
Adjustments to reconcile net loss to net cash used in operating activities:
Expenses paid on behalf of Company by related party	24,300
Depreciation and amortization	347	47,945
Stock-based compensation	1,763,950
Changes in operating assets and liabilities:
Inventories	(50,473)	4,348
Accounts receivable	263
Prepaid expenses	95,000	15,250
Deferred revenue	49,000
Accounts payable and accrued expenses	61,541	2,307
Net Cash Used In Operating Activities	(382,942)	(58,729)
Cash flows from investing activities:
Purchase of equipment	(4,163)
Net Cash Provided by Investing Activities	(4,163)
Cash flows from financing activities:
Payment on bank overdraft	(762)
Proceeds from sale of common stock	1,000,000	40,000
Proceeds from exercise of warrants	500,000
Proceeds from notes payable	25,000
Payment of notes payable	(1,820)
Proceeds from related parties	2,500	8,250
Payment of related party payables	(41,038)	(8,250)
Net Cash Provided by Financing Activities	1,483,880	40,000
Effect of exchange rate on cash	406	(599)
Net increase (decrease) in cash	1,097,181	(19,328)
Cash and cash equivalents - Beginning of period		27,124
Cash and cash equivalents - End of period	1,097,181	7,796
Cash paid for:
Interest
Income taxes
Supplementary disclosure of non-cash investing and financing activites
Common stock issued for services	1,763,950
Common stock issued for deposit on acquisition	$ 1,850,000

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	6 Months Ended
	Jul. 31, 2018
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The consolidated balance sheet as of July 31, 2018 and the consolidated statements of operations and cash flows for the periods presented have been prepared by Nutriband, Inc. and Subsidiary (the "Company" or "Nutriband") and are unaudited. The consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods, and consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations, changes in stockholders' equity and cash flows for all periods presented have been made. The information for the consolidated balance sheet as of January 31, 2018 was derived from audited financial statements of the Company. Organization Nutriband Inc. (the “Company” or “Nutriband”) was incorporated in the State of Nevada in January 2016. In January 2016, the Company acquired Nutriband Ltd. (“Nutriband Ltd”), a company registered in Dublin, Ireland, to enter the health and wellness market with new applications of transdermal patches. Nutriband Ltd. moved manufacturing and operations to the United States during 2016. Since then, Nutriband has developed a full line of consumer and health products which it primarily sells internationally. Through development and acquisition strategy, the Company has furthermore developed a pipeline for transdermal prescription medications. For the Company’s planned operations in the U.S., it will be subject to the rules of the Food and Drug Administration (“FDA”); the Company plans to seek FDA clearance, where required, for its transdermal patches and other products marketed in the U.S. According to the advice of our FDA counsel, Nutriband products are regulated as drugs by the FDA and must go through the relevant development pipeline as such before receiving market approval. Nutriband products have not been sold and are currently not available for sale within the United States, as the Company had sought further legal advice on their classification. Significant Accounting Policies The Company’s significant accounting policies are found below. These policies should be read in conjunction with Note 1 found in the Company’s Annual Report on Form 10-K for the year ended January 31, 2018. Principles of Consolidation The consolidated financial statements of the Company include the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Evaluation of Long-lived Assets Patents represent an important component of the Company’s total assets. The Company amortizes its patents on a straight-line basis over the estimated useful lives of the assets. Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value. As of January 31, 2018, the Company recorded an impairment charge of $2,500,000 and reduced the book value of the patent to be $-0-. Recently Adopted Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09””), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. Subsequently, the FASB issued several other updates related to revenue recognition (collectively with ASU 201-09, the “new revenue standards”). The Company adopted the guidance under the new revenue standards using the modified retrospective method effective February 1, 2018. The Company does not expect the adoption of the new revenue standards to have a material impact on its consolidated financial statements. Accounting Standards Issued But Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance. This guidance is effective for the annual periods and interim periods beginning December 15, 2018. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. Early adoption is permitted. The update guidance requires a modified retrospective adoption. We are currently in the process of evaluating this new standard update The Company has implemented all new pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial statements or results of operations. Reclassifications Certain items have been reclassified to conform to present year presentation.

Inventories

Inventories	6 Months Ended
	Jul. 31, 2018
Inventory Disclosure [Abstract]
INVENTORIES	2. INVENTORIES Inventory as of July 31, 2018 and January 31, 2018 are as follows: July 31, January 31, 2018 2018 Finished goods $ 4,133 $ 4,133 Work in progress 50,473 - Raw materials - - $ 54,606 $ 4,133

Debt

Debt	6 Months Ended
	Jul. 31, 2018
Debt Disclosure [Abstract]
DEBT	3. DEBT Due to related parties as of July 31, 2018 and January 31, 2018, consists of loans from officers and related parties, that are interest free and due on demand. As of July 31, 2018, and January 31, 2018, short-term debt due to related parties amounted to $-0- and $14,230, respectively. The loans were paid in full May 2018. Notes payable as of July 31, 2018 and January 31, 2018, consists of a loan from South County Dublin Council that is interest free with monthly payments of $75. The loan was due October 2017. As of July 31, 2018, and January 31, 2018, the total balance of long-term debt (current portion) amounted to $-0- and $1,820, respectively. The loan was paid in full July 2018. On September 12, 2017, the Company received an interest-free loan from TII Jet Services LDA in the amount of $15,000. The Company received an additional advance of $25,000 during April 2018. The loan is interest free and due upon demand. As of July 31, 2018, and January 31, 2018, the balance due was $40,000 and $15,000, respectively, and amount is included in notes payable.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jul. 31, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	4. RELATED PARTY TRANSACTIONS a) As of July 31, 2018, and January 31, 2018, Ann Sheridan, mother of the Chief Executive Officer and a Director of Nutriband Limited (Ireland), advanced the Company $-0- and $10,230, respectively, for operating capital. The advance is interest free and due on demand. The advance was repaid in full May 2018. b) During the year ended January 31, 2018, the Chief Financial Officer advanced $8,250 to the Company, all of which was repaid as of January 31, 2018. Additionally, the Company had amounts owed to the CFO for payments made on behalf of the Company of $30,800 and $4,000 as of April 30, 2018 and January 31, 2018, respectively. The amounts were repaid in full May 2018.

Common Stock

Common Stock	6 Months Ended
	Jul. 31, 2018
Equity [Abstract]
COMMON STOCK	5. COMMON STOCK The Company issued 322,000 shares valued at $1,763,950 during the six months ended July 31, 2018 for services provided to the Company. On May 2, 2018, the Company received proceeds of $1 million from Barandnic Holdings Ltd. In connection with the sale of 250,000 shares of the Company’s common stock. In connection with the sale, the purchaser received a 30-day warrant to purchase 250,000 shares at an exercise price of $4.00 per share. On May 27, 2018, Barandnic Holdings Ltd. exercised 125,000 common stock warrants and the Company received proceeds of $500,000. On June 2, 2018, the balance of the warrants expired. On July 31, 2018, the Company issued 250,000 shares of common stock valued at $1,850,000 as a down payment in connection with the acquisition of 4P Therapeutics, LLC. In addition to these shares, the Company also made a payment of $400,000 in August to complete the acquisition.

Warrants

Warrants	6 Months Ended
	Jul. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
WARRANTS	6. WARRANTS The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company’s common stock issued to non-employees of the Company. Exercise Remaining Intrinsic Shares Price Life Value Outstanding, January 31, 2018 730,000 $ 1.58 1.35 years $ - Granted 250,000 4.00 - - Expired/Cancelled (125,000 ) 4.00 - - Exercised (125,000 ) 4.00 - - Outstanding-period ending July 31, 2018 730,000 $ 1.58 0.85 years $ 4,247,000 Exercisable - period ending July 31, 2018 730,000 $ 1.58 0.85 years $ 4,247,000

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jul. 31, 2018
Earnings Per Share [Abstract]
EARNINGS PER SHARE	7. EARNINGS PER SHARE Basic earnings per common share are computed by dividing net earnings by the weighted average number of common shares outstanding during the period. Diluted earnings per common share are computed by dividing net earnings by the weighted average number of common shares and potential common shares outstanding during the period. Potential common shares consist of outstanding common stock purchase warrants. As of July 31, 2018, there were 730,000 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

Subsequent Events

Subsequent Events	6 Months Ended
	Jul. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	8. SUBSEQUENT EVENTS On April 5, 2018, the Company entered into an acquisition agreement to acquire a 100% interest in 4P Therapeutics Inc. in exchange for $400,000 and 250,000 shares of common stock of the Company. The shares were issued in July 2018 and payment made in August 2018 to complete the acquisition. 4P Therapeutics Inc. will become the pharmaceutical and development arm of Nutriband with specific focus on Transdermal and Topical Technologies, prescription drugs and clinical development. On June 13, 2018, the Company signed a letter of intent to acquire 100% of Carmel Biosciences, a pharmaceutical company that addresses critical needs in new drug and liquid reformulation for cardiovascular and metabolic therapies. The Company plans to complete the acquisition, valued at approximately $3.3 million, through payment of the issuance of 450,000 shares of the Company’s common stock. In December 2007, Carmel Biosciences received FDA approval for PREXXARTAN, the first and only approved oral liquid dosage form of the angiotensin receptor block (ARB) valsartan in the United States. The Company is still reviewing and conducting its due diligence on the acquisition and there is no current estimated time of completion. The Company’s Board of Directors voted on July 27, 2018 to rescind the May 22, 2017 Share Exchange Agreement between Nutriband Inc. and Advanced Health Brands, Inc. due to Advanced Health Brands, Inc.’s failure to deliver consideration in exchange for shares in Nutriband. We engaged counsel to obtain a legal judgment to recover the stock, to rescind the transaction, or to otherwise cancel the stock we issued in the transaction. On July 27, 2018, our counsel filed in the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, a Verified Complaint against Advanced Health Brands, Inc., Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without Notice and a Motion for Prejudgment Writ of Replevin. On August 2, 2018, the court entered a Temporary Injunction Without Notice and an Order to Show Cause against Defendants. Defendants Kalmar, Murphy, Polly-Murphy, and Baker have filed a Motion to Dismiss Nutriband’s Verified Complaint, Motion to Dissolve Temporary Injunction Without Notice and Response to Order to Show Cause, and Motion to Compel Arbitration. The parties presented oral arguments to the Court concerning their respective motions and pleadings on August 22, 2018 and again on August 24, 2018, but the Court has yet to rule on any motion or issue presented. On August 22, 2018, Kalmar, Murphy, Polly-Murphy, and Baker filed a Complaint against Nutriband in the Franklin County, Ohio Court of Common Pleas seeking a declaratory judgment permitting them to sell their Nutriband shares. We are actively working on engaging Ohio counsel to defend against this lawsuit. The parties are currently scheduled to continue their respective oral arguments before the Florida court on December 7, 2018. On August 10, 2018, the Company received a Wells notice from the Enforcement Division staff of the U.S. Securities and Exchange Commission, Miami Regional Office. The Enforcement Division staff is conducting an investigation into the Company’s disclosures about the FDA requirements for its transdermal patch products made in the Company’s Form 10 Registration Statement and amendments (filed June 2, 2016) and Form 10-K Report (filed May 8, 2017). In the Wells notice, the enforcement division staff informed the Company that it intended to recommend that the Commission authorize a civil injunctive action alleging that the Company, its CEO, and CFO (“Officers”) violated certain provisions of the federal securities laws, including Sections 10(b) and 13(a) of the Securities Exchange Act of 1934, with respect to the Company’s FDA disclosures in its public filings. On September 7, 2018, the Company and Officers filed a Wells Submission with the Enforcement Division staff explaining why they did not violate the federal securities laws and why the Commission should not file a civil injunctive action and not seek civil monetary penalties and other forms of equitable relief. The Enforcement Division staff is reviewing the Wells Submission at this time. It is the Company’s belief that the statutory and rules violations alleged by the Commission’s Enforcement Division staff in the Wells notice are without merit.

Description of Business and S14

Description of Business and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jul. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements of the Company include the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Evaluation of Long-lived Assets	Evaluation of Long-lived Assets Patents represent an important component of the Company’s total assets. The Company amortizes its patents on a straight-line basis over the estimated useful lives of the assets. Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value. As of January 31, 2018, the Company recorded an impairment charge of $2,500,000 and reduced the book value of the patent to be $-0-.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09””), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. Subsequently, the FASB issued several other updates related to revenue recognition (collectively with ASU 201-09, the “new revenue standards”). The Company adopted the guidance under the new revenue standards using the modified retrospective method effective February 1, 2018. The Company does not expect the adoption of the new revenue standards to have a material impact on its consolidated financial statements.
Accounting Standards Issued But Not Yet Adopted	Accounting Standards Issued But Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance. This guidance is effective for the annual periods and interim periods beginning December 15, 2018. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. Early adoption is permitted. The update guidance requires a modified retrospective adoption. We are currently in the process of evaluating this new standard update The Company has implemented all new pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial statements or results of operations.
Reclassifications	Reclassifications Certain items have been reclassified to conform to present year presentation.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jul. 31, 2018
Inventory Disclosure [Abstract]
Schedule of inventories	July 31, January 31, 2018 2018 Finished goods $ 4,133 $ 4,133 Work in progress 50,473 - Raw materials - - $ 54,606 $ 4,133

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jul. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Schedule of warrants	Exercise Remaining Intrinsic Shares Price Life Value Outstanding, January 31, 2018 730,000 $ 1.58 1.35 years $ - Granted 250,000 4.00 - - Expired/Cancelled (125,000 ) 4.00 - - Exercised (125,000 ) 4.00 - - Outstanding-period ending July 31, 2018 730,000 $ 1.58 0.85 years $ 4,247,000 Exercisable - period ending July 31, 2018 730,000 $ 1.58 0.85 years $ 4,247,000

Description of Business and S17

Description of Business and Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jan. 31, 2018USD ($)
Description of Business and Summary of Significant Accounting Policies (Textual)
Impairment charge	$ 2,500,000
Reduced the book value patents	$ 0

Inventories (Details)

Inventories (Details) - USD ($)	Jul. 31, 2018	Jan. 31, 2018
Inventory Disclosure [Abstract]
Finished goods	$ 4,133	$ 4,133
Work in progress	50,473
Raw materials
Inventories, Net	$ 54,606	$ 4,133

Debt (Details)

Debt (Details) - USD ($)	1 Months Ended	6 Months Ended	12 Months Ended
	Apr. 30, 2018	Jul. 31, 2018	Jan. 31, 2018	Sep. 12, 2017
Debt (Textual)
Short-term debt		$ 0	$ 14,230
Short-term debt monthly payments		75	75
Total balance of long-term debt		0	1,820
Interest-free loan from TII Jet Services LDA				$ 15,000
Additional advance received	$ 25,000
Balance due		$ 40,000	$ 15,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended	12 Months Ended
	Apr. 30, 2018	Jan. 31, 2018	Jul. 31, 2018
Chief Financial Officer [Member]
Related Party Transactions (Textual)
Amount advances to company		$ 8,250
Additional expenses paid	$ 30,800	4,000
Ann Sheridan [Member]
Related Party Transactions (Textual)
Advance from related party		$ 10,230	$ 0

Common Stock (Details)

Common Stock (Details) - Common stock [Member] - USD ($)	May 27, 2018	May 02, 2018	Jul. 31, 2018
Common Stock (Textual)
Shares issued for services			322,000
Shares issued for services, value			$ 1,763,950
Common stock issued in acquisition, shares			250,000
Common stock issued in acquisition, value			$ 1,850,000
Payment for acquisition			$ 400,000
Barandnic Holdings Ltd. [Member]
Common Stock (Textual)
Issuance shares of common stock, shares		250,000
Proceeds from common stock received	$ 500,000	$ 1,000,000
Warrant to purchase of common stock		250,000
Warrant maturity date		30 days
Exercise price of warrants		$ 4
Common stock warrants exercised	125,000

Warrants (Details)

Warrants (Details)	6 Months Ended
	Jul. 31, 2018USD ($)$ / sharesshares
Shares
Outstanding, Ending Balance	730,000
Warrants [Member]
Shares
Outstanding, Beginning Balance	730,000
Granted	250,000
Expired/Cancelled	(125,000)
Exercised	(125,000)
Outstanding, Ending Balance	730,000
Exercisable	730,000
Exercise Price
Outstanding, Beginning Balance | $ / shares	$ 1.58
Granted | $ / shares	4
Expired/Cancelled | $ / shares	4
Exercised | $ / shares	4
Outstanding, Ending Balance | $ / shares	1.58
Exercisable | $ / shares	$ 1.58
Remaining Life
Outstanding, Beginning period	1 year 4 months 6 days
Outstanding, Ending period	10 months 6 days
Exercisable	10 months 6 days
Intrinsic Value
Outstanding, Beginning Balance | $
Outstanding, Ending Balance | $	4,247,000
Exercisable | $	$ 4,247,000

Earnings Per Share (Details)

Earnings Per Share (Details)	Jul. 31, 2018shares
Earnings Per Share (Textual)
Common stock equivalents outstanding	730,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Jun. 13, 2018	Apr. 05, 2018
Carmel Biosciences [Member]
Subsequent Events (Textual)
Acquisition percentage	100.00%
Business acquisition, description	The Company plans to complete the acquisition, valued at approximately $3.3 million, through payment of the issuance of 450,000 shares of the Company’s common stock.
4P Therapeutics Inc. [Member]
Subsequent Events (Textual)
Acquisition percentage		100.00%
Issuance shares of common stock, value		$ 400,000
Issuance shares of common stock, shares		250,000